New York, NY, United States of America

Clarapath, Inc.


USPTO Granted Patents = 31

Trademarks = 3

Forward Citations = 185

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Partha Pratim Mitra (30 out of 31 patents)

silverMedal Baris Yagci (20 out of 20 patents)

bronzeMedal Cong Zhang (16 out of 16 patents)

4.  Charles Cantor (13 out of 101 patents)

5.  Janak Sewkarran (7 out of 7 patents)

6.  Robert Shusko (6 out of 7 patents)

7.  David Kleinfeld (6 out of 6 patents)

8.  Steven Smith (6 out of 6 patents)

9.  Jerry R Pinto (5 out of 5 patents)

10.  Mark Fasciano (4 out of 6 patents)

11.  Eric Feinstein (4 out of 4 patents)

12.  Alexander S Tolpygo (2 out of 2 patents)

13.  Robert L Kleinberg (2 out of 43 patents)

14.  Weston Smith (1 out of 1 patent)

15.  Jonathan Gardi (1 out of 1 patent)


Core Competencies:
Automated Tissue Sectioning
Microtomy
Pathology Sample Preparation
Quality Control
High Throughput Systems
Cut Quality Prediction
Histology
Spatial Genomics
Tissue Biobank
Epoxy-Siloxane Compositions
Tape Transport Automation

31 patents:

Clarapath, Inc. is a New York-based company specializing in innovative solutions for pathology and diagnostics. The organization focuses on developing advanced imaging technologies and software that enhance the accuracy and efficiency of tissue analysis. By integrating cutting-edge artificial intelligence and machine learning techniques, Clarapath aims to transform traditional pathology workflows, enabling healthcare professionals to make more informed decisions. Their commitment to improving patient outcomes positions them as a key player in the medical technology landscape.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Clarapath, Inc.
31 Patents

#280 in New York, NY

#654 in New York

#10,912 in US

#21,217 in the World

New York, NY (US)
New York, NY, United States of America
Forward Citations = 185

16 inventors:

Please report any incorrect information to [email protected]
Loading…